Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shandong Longertek Technology Co Ltd
SZSE:300594
|
CN |
Genfit SA
Accrued Liabilities
Genfit SA
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Accrued Liabilities
€3k
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-77%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Accrued Liabilities
€35m
|
CAGR 3-Years
31%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
|
Inventiva SA
PAR:IVA
|
Accrued Liabilities
€5.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Accrued Liabilities
$10.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
10%
|
|
|
DBV Technologies SA
PAR:DBV
|
Accrued Liabilities
$14.3m
|
CAGR 3-Years
34%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
11%
|
|
|
Abivax SA
PAR:ABVX
|
Accrued Liabilities
€4.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's Accrued Liabilities?
Accrued Liabilities
3k
EUR
Based on the financial report for Dec 31, 2025, Genfit SA's Accrued Liabilities amounts to 3k EUR.
What is Genfit SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
-77%
Over the last year, the Accrued Liabilities growth was -100%. The average annual Accrued Liabilities growth rates for Genfit SA have been -91% over the past three years , -77% over the past five years .
